

High-Risk HPV Testing in Head and Neck Carcinoma: Key Updates from the 2025 College of American Pathologists Guideline.

Title: High-Risk HPV Testing in Head and Neck Carcinoma: Key Updates from the 2025 College of American Pathologists Guideline.

Publication year: 2025

Journal: Head and neck pathology

Authors: Department of Pathology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, WRN 219, Boston, MA, 02114, USA. Wfaquin@mgh.harvard.edu.

Society: College of American Pathologists

Origin country: United States

Target countries: United States

DOI: 10.1007/s12105-025-01847-2

PMID: 41021082

Source: <https://pubmed.ncbi.nlm.nih.gov/41021082/>

Head Neck Pathol Head Neck Pathol 956 hnpa 101304010 Head and Neck Pathology 1936-055X 1936-0568 Springer PMC12480157 PMC12480157.1 12480157 12480157 41021082 10.1007/s12105-025-01847-2 1847 1 Review High-Risk HPV Testing in Head and Neck Carcinoma: Key Updates from the 2025 College of American Pathologists Guideline <http://orcid.org/0000-0002-1174-3972> Faquin William C. Wfaquin@mgh.harvard.edu 1 Lewis James S. Jr. 2 Beadle Beth 3 Bishop Justin A. 4 Chernock Rebecca D. 5 Krane Jeffrey F. 6 Moncur Joel T. 7 Rocco James W. 8 Schwartz Mary R. 9 Seethala Raja R. 10 1 <https://ror.org/002pd6e78> grid.32224.35 0000 0004 0386 9924 Department of Pathology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, WRN 219, Boston, MA 02114 USA 2 <https://ror.org/03jp40720> grid.417468.8 0000 0000 8875 6339 Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale, AZ USA 3 <https://ror.org/00f54p054> grid.168010.e 0000000419368956 Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA USA 4 <https://ror.org/05byvp690> grid.267313.2 0000 0000 9482 7121 Department of Pathology, UT Southwestern Medical Center, Dallas, TX USA 5 <https://ror.org/01yc7t268> grid.4367.6 0000 0001 2355 7002 Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO USA 6 <https://ror.org/046rm7j60> grid.19006.3e 0000 0000 9632 6718 Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA USA 7 <https://ror.org/00fj8a872> grid.453125.4 Office of the Director, The Joint Pathology Center, Silver Springs, MD USA 8 <https://ror.org/00c01js51> grid.412332.5 0000 0001 1545 0811 Department of Otolaryngology- Head and Neck Surgery, Ohio State University Wexner Medical Center, Columbus, OH USA 9 <https://ror.org/027zt9171> grid.63368.38 0000 0004 0445 0041 Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX USA 10 <https://ror.org/04ehec288> grid.412689.0 0000 0001 0650 7433 Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA USA 29 9 2025 12 2025 19 1 478925 115 14 8 2025 6 9 2025 29 09 2026 07 01 2026 21 01 2026 © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 2025 High-risk human papillomavirus (HPV) plays a significant role in the pathogenesis of certain head and neck (HN) cancers, especially squamous cell carcinomas (SCC) arising in the oropharynx. Distinction between HPV-independent and HPV-associated HNSCC has important implications for clinical management and patient prognosis in specific anatomic subsites of the head and neck. In 2018, the College of American Pathologists (CAP) issued 14 evidence-based guideline statements related to the testing, application, interpretation, and reporting of HPV and surrogate marker testing for HN carcinomas. Since that

time, significant amounts of new data have been published which serves as the foundation for the updated 2025 CAP Guideline resulting in 16 evidence-based recommendations. These statements refine issues related to the application of high-risk HPV testing in patients with HNSCC, and they address some issues not fully covered in the 2018 CAP Guideline. This brief review discusses the changes that were made to the original guideline and provides a quick reference for the testing recommendations across head and neck sites.